1) To understand the value and challenges of using the Banff criteria for the diagnosis of antibody-mediated rejection.
2) To share the survey results on how antibody-mediated rejection is diagnosed and managed in different institutions worldwide.*
3) To learn the personal and institutional experience on how antibody-mediated rejection is diagnosed and managed from experts.
*A survey on the diagnosis and management of antibody-mediated rejection will be designed by the Pathology Committee and will be distributed to all ILTS members as well as the Hans Popper Hepatopathology Society members in early January 2022. The data will be collected and analyzed in March before the workshop.
Hanlin L. Wang (United States)
Jimin (Nancy) Liu (Canada)
to view this session in the congress program.